Type 2 diabetes and gender differences in liver cancer by considering different confounding factors: a meta-analysis of cohort studies

Annals of Epidemiology

Volumn 26, Issue 11, 2016, Pages 764-772

  Wang, Yuqin ^a   Wang, Baochan ^a   Yan, Shiyan ^a   Shen, Feng ^a   Cao, Haixia ^a   Fan, Jiangao ^a   Zhang, Rongrong ^a   Gu, Jun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cohort study; Liver cancer; Meta analysis; Type 2 diabetes

Indexed keywords

ALCOHOL CONSUMPTION; ARTICLE; ASIAN; BODY MASS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONFOUNDING VARIABLE; CORRELATIONAL STUDY; DISEASE ASSOCIATION; EMBASE; FEMALE; HIGH RISK POPULATION; HUMAN; LIVER CANCER; MALE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SMOKING; COMORBIDITY; COMPARATIVE STUDY; EPIDEMIOLOGY; INCIDENCE; LIVER TUMOR; META ANALYSIS; PROGNOSIS; RISK ASSESSMENT; SEX FACTOR; SURVIVAL ANALYSIS;

BODY MASS INDEX; COHORT STUDIES; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; PROGNOSIS; RISK ASSESSMENT; SEX FACTORS; SMOKING; SURVIVAL ANALYSIS;

EID: 84994845894     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2016.09.006     Document Type: Article

References (61)

1. [1] Altekruse, S.F., Henley, S.J., Cucinelli, J.E., McGlynn, K.A., Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 109 (2014), 542–553.
2. [2] McGlynn, K.A., Petrick, J.L., London, W.T., Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 19 (2015), 223–238.
3. [3] N. Howlader, A.M. Noone, M. Krapcho, J. Garshell, N. Neyman, S.F. Altekruse, et al. SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/archive/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013. Accessed December 1, 2013.
4. [4] Lafaro, K.J., Demirjian, A.N., Pawlik, T.M., Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 24 (2015), 1–17.
5. [5] De Bruijn, K.M., Arends, L.R., Hansen, B.E., Leeflang, S., Ruiter, R., van Eijck, C.H., Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg 100 (2013), 1421–1429.
6. [6] Zhang, Z.H., Su, P.Y., Hao, J.H., Sun, Y.H., The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int J Gynecol Cancer 23 (2013), 294–303.
7. [7] Ben, Q., Cai, Q., Li, Z., Yuan, Y., Ning, X., Deng, S., et al. The relationship between new-onset diabetes mellitus and pancreatic cancer risk: A case-control study. Eur J Cancer 48 (2011), 248–254.
8. [8] Ben, Q., Xu, M., Ning, X., Liu, J., Hong, S., Huang, W., et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 47 (2011), 1928–1937.
9. [9] Wang, C., Wang, X., Gong, G., Ben, Q., Qiu, W., Chen, Y., et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 130 (2012), 1639–1648.
10. [10] Atchison, E.A., Gridley, G., Carreon, J.D., Leitzmann, M.F., McGlynn, K.A., Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 128 (2011), 635–643.
11. [11] Hense, H.W., Kajuter, H., Wellmann, J., Batzler, W.U., Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort. Diabetol Metab Syndr, 3, 2011, 15.
12. [12] Campbell, P.T., Newton, C.C., Patel, A.V., Jacobs, E.J., Gapstur, S.M., Diabetes and cause-specific mortality in a prospective cohort of one million u.s. Adults. Diabetes Care 35 (2012), 1835–1844.
13. [13] Zhang, P.H., Chen, Z.W., Lv, D., Xu, Y.Y., Gu, W.L., Zhang, X.H., et al. Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China. BMC Public Health, 12, 2012, 567.
14. [14] Koh, W.P., Wang, R., Jin, A., Yu, M.C., Yuan, J.M., Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer 108 (2013), 1182–1188.
15. [15] Lai, G.Y., Park, Y., Hartge, P., Hollenbeck, A.R., Freedman, N.D., The association between self-reported diabetes and cancer incidence in the NIH-AARP Diet and Health Study. J Clin Endocrinol Metab 98 (2013), E497–E502.
16. [16] Nakamura, K., Wada, K., Tamai, Y., Tsuji, M., Kawachi, T., Hori, A., et al. Diabetes mellitus and risk of cancer in Takayama: a population-based prospective cohort study in Japan. Cancer Sci 104 (2013), 1362–1367.
17. [17] Tseng, C.H., Diabetes is not an independent risk factor for hepatocellular carcinoma. Diabetes Metab Res Rev 29 (2013), 515–524.
18. [18] Walker, J.J., Brewster, D.H., Colhoun, H.M., Fischbacher, C.M., Leese, G.P., Lindsay, R.S., et al. Type 2 diabetes, socioeconomic status and risk of cancer in Scotland 2001-2007. Diabetologia 56 (2013), 1712–1715.
19. [19] Chiang, C.H., Lee, L.T., Hung, S.H., Lin, W.Y., Hung, H.F., Yang, W.S., et al. Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly. Hepatology 59 (2014), 2207–2215.
20. [20] Oberaigner, W., Ebenbichler, C., Oberaigner, K., Juchum, M., Schonherr, H.R., Lechleitner, M., Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol/Austria. BMC Public Health, 14, 2014, 1058.
21. [21] Shen, C., Schooling, C.M., Chan, W.M., Lee, S.Y., Leung, G.M., Lam, T.H., Self-reported diabetes and mortality in a prospective Chinese elderly cohort study in Hong Kong. Prev Med 64 (2014), 20–26.
22. [22] Wideroff, L., Gridley, G., Mellemkjaer, L., Chow, W.H., Linet, M., Keehn, S., et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89 (1997), 1360–1365.
23. [23] Coughlin, S.S., Calle, E.E., Teras, L.R., Petrelli, J., Thun, M.J., Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159 (2004), 1160–1167.
24. [24] Jee, S.H., Ohrr, H., Sull, J.W., Samet, J.M., Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst 96 (2004), 1851–1856.
25. [25] Inoue, M., Iwasaki, M., Otani, T., Sasazuki, S., Noda, M., Tsugane, S., Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166 (2006), 1871–1877.
26. [26] Chodick, G., Heymann, A.D., Rosenmann, L., Green, M.S., Flash, S., Porath, A., et al. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control 21 (2010), 879–887.
27. [27] Zhou, X.H., Qiao, Q., Zethelius, B., Pyorala, K., Soderberg, S., Pajak, A., et al. Diabetes, prediabetes and cancer mortality. Diabetologia 53 (2010), 1867–1876.
28. [28] Wang, P., Kang, D., Cao, W., Wang, Y., Liu, Z., Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 28 (2012), 109–122.
29. [29] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
30. [30] Zendehdel, K., Nyren, O., Ostenson, C.G., Adami, H.O., Ekbom, A., Ye, W., Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95 (2003), 1797–1800.
31. [31] Shu, X., Ji, J., Li, X., Sundquist, J., Sundquist, K., Hemminki, K., Cancer risk among patients hospitalized for Type 1 diabetes mellitus: a population-based cohort study in Sweden. Diabet Med 27 (2010), 791–797.
32. [32] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
33. [33] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
34. [34] Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994), 1088–1101.
35. [35] Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
36. [36] Duval, S., Tweedie, R., Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
37. [37] Thompson, S.G., Sharp, S.J., Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18 (1999), 2693–2708.
38. [38] Adami, H.O., Chow, W.H., Nyren, O., Berne, C., Linet, M.S., Ekbom, A., et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88 (1996), 1472–1477.
39. [39] Uetake, S., Yamauchi, M., Itoh, S., Kawashima, O., Takeda, K., Ohata, M., Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen- and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection. Alcohol Clin Exp Res 27 (2003), 47S–51S.
40. [40] El-Serag, H.B., Tran, T., Everhart, J.E., Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126 (2004), 460–468.
41. [41] Jee, S.H., Ohrr, H., Sull, J.W., Yun, J.E., Ji, M., Samet, J.M., Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293 (2005), 194–202.
42. [42] Ioannou, G.N., Splan, M.F., Weiss, N.S., McDonald, G.B., Beretta, L., Lee, S.P., Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 5 (2007), 938–945 945.e1–4.
43. [43] Khan, M., Mori, M., Fujino, Y., Shibata, A., Sakauchi, F., Washio, M., et al. Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pac J Cancer Prev 7 (2006), 253–259.
44. [44] Verlato, G., Zoppini, G., Bonora, E., Muggeo, M., Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 26 (2003), 1047–1051.
45. [45] Yu, M.W., Chen, C.J., Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 53 (1993), 790–794.
46. [46] Farinati, F., De Maria, N., Marafin, C., Fagiuoli, S., Della Libera, G., Naccarato, R., Hepatocellular carcinoma in alcoholic cirrhosis: is sex hormone imbalance a pathogenetic factor?. Eur J Gastroenterol Hepatol 7 (1995), 145–150.
47. [47] Ahmed, F., Perz, J.F., Kwong, S., Jamison, P.M., Friedman, C., Bell, B.P., National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003. Prev Chronic Dis 5 (2008), A74–A84.
48. [48] Setiawan, V.W., Hernandez, B.Y., Lu, S.C., Stram, D.O., Wilkens, L.R., Marchand, L.L., et al. Diabetes and racial/ethnic differences in hepatocellular carcinoma risk: the multiethnic cohort. J Natl Cancer Inst, 106, 2014.
49. [49] Welzel, T.M., Graubard, B.I., Quraishi, S., Zeuzem, S., Davila, J.A., El-Serag, H.B., et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 108 (2013), 1314–1321.
50. [50] Makarova-Rusher, O.V., Altekruse, S.F., McNeel, T.S., Ulahannan, S., Duffy, A.G., Graubard, B.I., et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer 122 (2016), 1757–1765.
51. [51] Weng, C.J., Hsieh, Y.H., Tsai, C.M., Chu, Y.H., Ueng, K.C., Liu, Y.F., et al. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 17 (2010), 1808–1815.
52. [52] Longato, L., de la Monte, S., Kuzushita, N., Horimoto, M., Rogers, A.B., Slagle, B.L., et al. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 49 (2009), 1935–1943.
53. [53] Papa, S., Bubici, C., Zazzeroni, F., Franzoso, G., Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways. Biol Chem 390 (2009), 965–976.
54. [54] Park, E.J., Lee, J.H., Yu, G.Y., He, G., Ali, S.R., Holzer, R.G., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140 (2010), 197–208.
55. [55] Stocks, T., Rapp, K., Bjorge, T., Manjer, J., Ulmer, H., Selmer, R., et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med, 6, 2009, e1000201.
56. [56] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J Clin 61 (2011), 69–90.
57. [57] Okura, Y., Urban, L.H., Mahoney, D.W., Jacobsen, S.J., Rodeheffer, R.J., Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 57 (2004), 1096–1103.
58. [58] Chen, H.P., Shieh, J.J., Chang, C.C., Chen, T.T., Lin, J.T., Wu, M.S., et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62 (2013), 606–615.
59. [59] Singh, S., Singh, P.P., Singh, A.G., Murad, M.H., Sanchez, W., Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 108 (2013), 881–891 quiz 892.
60. [60] Lai, S.W., Chen, P.C., Liao, K.F., Muo, C.H., Lin, C.C., Sung, F.C., Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 107 (2012), 46–52.
61. [61] Nkontchou, G., Cosson, E., Aout, M., Mahmoudi, A., Bourcier, V., Charif, I., et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 96 (2011), 2601–2608.